Nanosuspensions as the most promising approach in nanoparticulate drug delivery systems

Pharmazie

Volumn 59, Issue 1, 2004, Pages 5-9

  Rao, G Chandra Sekhara ^a   Kumar, M Satish ^a   Mathivanan, N ^a   Rao, M E Bhanoji ^a  

^a ROLAND INSTITUTE OF PHARMACEUTICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; CALCITONIN; CELLACEFATE; CHITOSAN; CLOBETASOL PROPIONATE; DACTINOMYCIN; DOXORUBICIN; IDARUBICIN; INSULIN; LEUCINE ENKEPHALIN[2 DEXTRO ALANINE 6 ARGININE]; LIPOSOME; LOPERAMIDE; NANOPARTICLE; PILOCARPINE; PILOPLEX; POLY(HEXYL 2 CYANOACRYLATE); POLY(METHYL METHACRYLATE); POLYGLACTIN; POLYSORBATE 80; POLYSTYRENE; PRIMORDIALE; SOLID LIPID NANOPARTICLE; TIMOLOL; TUBOCURARINE CHLORIDE; UNCLASSIFIED DRUG; VINCAMINE;

BLOOD BRAIN BARRIER; COLLOID; CRYSTAL; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; DRUG STABILITY; GENETIC ENGINEERING; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; MACROMOLECULE; MACROPHAGE; POLYMERIZATION; RETICULOENDOTHELIAL SYSTEM; REVIEW; SUSPENSION;

DRUG DELIVERY SYSTEMS; LIPIDS; MICROSPHERES; POLYMERS; SUSPENSIONS;

EID: 1642460578     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Ammoury N, Fessi H, Devissaguet JP, Puisieux F, Benita S (1990) In vitro release pattern of indomethacin from poly (DL-lactide) nanocapsules. J. Pharm. Sci. 79: 763-767.
2. Birrenbach G, Speiser P (1976) Polymerized micelles and their use as adjuvants in immunology. J. Pharm. Sci. 65: 1763-1766.
3. Couvreur P, Kante B, Roland M (1979) Polycyanoacrylate nanocapsules as potential lysosomotropic carriers: Preparation, morphological and sorptive properties. J. Pharm. Pharmacol. 31: 331-332.
4. Couvreur P, Kante B, Grislain L, Roland M, Speiser P (1982) Toxcity of poly alkylcyanoacrylate nanoparticles H. Doxorubicin-loaded nanoparticles. J. Pharm. Sci. 71: 790-792.
5. Gasco MR, Cavalli R, Carlotti ME (1992) Timolol in lipospheres. Pharmazie 47: 119-121.
6. Gasco MR (1993) Method for producing lipid microspheres having a narrow size distribution. US Patent. 5250236.
7. Grau MJ, Kayser O, Müller RH (2000) Nanosuspensions of poorly soluble drugs - reproducibility of small scale production. Int. J. Pharm. 196: 155-159.
8. Grislain L, Couvreur P, Lenaerts V, Roland M, Deprez, Decampenecre D, Speiser P (1983) Pharmacokinetics and distribution of a biodegradable drug-carrier. Int. J. Pharm. 15: 335-345.
9. Gurny R (1981a) Preliminary study of prolonged acting drug delivery system for the treatment of glaucoma. Pharm. Acta. Helv. 56: 130-132.
10. Gurny R, Peppas NA, Harrington DD, Banker GS (1981b) Development of biodegradable and injectable latices for controlled release of potent drugs. Drug Dev. Ind. Pharm. 7: 1.
11. Hiremath SRR, Hota A (1999) Nanoparticles as drug delivery systems. Indian J. Pharm. Sci. 61(2): 69-75.
12. Hu FQ, Yuan H, Zhang HH, Fang M (2002) Preparation of solid lipid nanoparticles with clobetasol propionate by a novel solvent diffusion method in aqueous system and physicochemical characterization. Int. J. Pharm. 239: 121-128.
13. Jacobs C, Müller RH (2002) Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm. Res. 19: 189-194.
14. Janes KA, Calvo P, Alonso MJ (2001) Polysaccharide colloidal particles as drug delivery systems for macromolecules. Adv. Drug Deliv. Rev. 47: 83-97.
15. Jia H, Wong H, Wang Y, Garza M, Weitman SD (2003) Carbendazime: Disposition, cellular permeability, metabolite identification and pharmacokinetic comparison with its nanoparticle: J. Pharm. Sci. 92: 161-172.
16. Kante B, Couvreur P, Dubois-Krack D et al. (1982) Toxicity of polyalkylcyanoacrylate nanoparticles. I. Free nanoparticles. J. Pharm. Sci. 71: 786-790.
17. Kramer PA (1974) Albumin microspheres as vehicles for achieving specificity in drug delivery. J. Pharm. Sci. 63: 1646-1647.
18. th world meeting ADRITELF/APV/APGI, Florence, p. 271-272.
19. Kreuter J (1983) Evaluation of nanoparticles as drug-delivery systems I. preparation methods. Pharma Acta Helv. 58: 196.
20. Kreuter J (1990) Large-scale production problems and manufacturing of nanoparticles. In: Tyle P (ed.) Specialized drug delivery systems, Marcel Dekker Inc., New York, p. 264.
21. Kreuter J (1994) Nanoparticles. In: Colloidal drug delivery systems, Marcel Dekker Inc., New York, p. 314.
22. Leroux J-C, Doelker E, Gurny RM (1996) The use of drug-loaded nanoparticles in cancer chemotherapy. In: Benita S (ed.) Microencapsulation, Marcel Dekker Inc., New York, p. 566.
23. Lippacher A, Müller RH, Mäder K (2000) Investigation on the viscoelastic properties of lipid based colloidal drug carriers. Int. J. Pharm. 196: 227-230.
24. Maincent P, Leverge R, Sado P, Couvreur P, Devissaguet JP (1986) Disposition kinetics and oral bioavailability of vincamine-loaded polyalkylcyanoacrylate nanoparticles. J. Pharm. Sci. 75: 955-958.
25. Marty JJ, Oppenheim RC, Speiser P (1978) Nanoparticles: a new colloidal drug delivery system. Pharm. Acta. Helv. 53: 17-23.
26. th International Symposium on Microencapsulation, London.
27. Müller RH, Mäder K, Gohla S (2000a) Solid lipid nanoparticles for controlled drug delivery; a review of the state of the art. Eur. J. Pharm. Biopharm. 50: 161-177.
28. Müller RH, Dingler A, Schneppe T, Gohla S (2000b) Large-scale production of solid lipid nanoparticles (SLN™) and nanosuspensions (DissoCubes™). In: Wise, T, Cichon, I, Stottmeister (ed.) Handbook of Pharmaceutical Controlled Release Technology, Marcel Dekker Inc., New York, p. 359-376.
29. Müller RH, Jacobs C, Kayser O (2001) Nanosuspensions as particulate drug formulations in therapy rationale for development and what we can expect for the future. Adv. Drug. Deliv. Rev. 47: 3-19.
30. Müller RH, Radtke M, Wissing SA (2002a) Nanostructured lipid matrices for improved microencapsulation of drugs. Int. J. Pharm. 242: 121-128.
31. Müller RH, Radtke M, Wissing SA (2002b) Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) in cosmetic and dermatological preparations. Adv. Drug Deliv. Rev. 54: 131-155.
32. th world meeting ADRITELF/APV/APGI, Florence. p. 769-770.
33. Olbrich A, Gessner A, Kayser O, Müller RH (2000) Lipid-drug-conjugate (LDC) nanoparticles as an alternative carrier system with high drug content. Intern. Symp. Control. Rel. Bioact. Mater. 27: 295-296.
34. PharmaSol, GMBH, 2001, PCT/EP00/06535.
35. Peters K, Leitzke S, Diederichs JE, Bomer K, Hahn H, Müller RH, Ehlers S (2000) Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine mycobacterium avium infection. J. Antimicrob. Chemother. 45: 77-83.
36. Puri V, Bansal AK (2001) Pharmaceutical Technology: Challenges and Opportunities. CRIPS-NIPER 2: 2-11.
37. Ravi Kumar MN (2000) Nano and microparticles as controlled drug delivery devices. J. Pharm. Pharm. Sci. 3: 234-258.
38. Sakuma S, Suzuki N, Kikuchi H, Hiwatari K, Arikawa K, Kishida A, Akashi M (1997a) Oral peptide delivery using nanoparticles composed of novel graft copolymers having hydrophobic backbone and hydrophilic branches. Int. J. Pharm. 149: 93.
39. Sakuma S, Suzuki N, Kikuchi H, Hiwatari K, Arikawa K, Kishida A, Akashi M (1997b) Absorption enhancement of orally administered salmon calcitonin by polystyrene nanoparticles having poly (N-isopropylacrylamide) branches on their surfaces. Int. J. Pharm. 158: 69-78.
40. Scheffel U, Rhodes BA, Natarajan TK, Wagner HN (1972) Albumin microspheres for the study of the reticuloendothelial systems. J. Nucl. Med. 13: 498-503.
41. Sjostrom B, Bergenstahl B (1992) Preparation of submicron drug particles in lecithin - stabilized o/w emulsions. I model studies of the precipitation of cholesteryl acetate. Int. J. Pharm. 88: 53.
42. Sjostrom B, Westensen K, Bergenstahl B (1993) Preparation of submicron drug particles in lecithin - stabilized o/w emulsions II. Characterization of cholesteryl acetate particles. Int. J. Pharm. 94: 89.
43. Tukeuchi H, Yamamoto H, Kawashima Y (2001) Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv. Drug Deliv. Rev. 47: 39-54.
44. Utreja S, Jain NK (2001) Solid Lipid Nanoparticles. In: Jain NK (ed.) Advances in controlled and Novel drug delivery, CBS Publishers, New Delhi, p. 409.
45. Vyas SP, Khar RK (2002) Nanoparticles In: Targeted and controlled drug delivery, CBS Publishers & Distributors, New Delhi, p. 351.
46. Westesen K, Siekmann B (1996) Biodegradable colloid drug carrier systems based on solid lipids. In: Simon Benita (ed.) Microencapsulation, Marcel Dekker Inc., New York, p. 232-254.
47. Westesen K (2000) Novel lipid-based colloidal dispersions as potential drug administration systems - expectations and reality. Coll. Polymer Sci. 278: 608-618.
48. Wilson CG, Zhu YP, Kurmala P, Rao LS, Dhillon B (2001) Ophthalmic drug delivery. In: Hillery AH, Lloyd AW, Swarbrick J (ed.) Drug delivery and targeting for pharmacists and pharmaceutical scientists, Taylor and Francis, Inc., New York, p 329-353.
49. Yang SC, Zhu JB (2002) Preparation and characterization of camptothecin solid lipid nanoparticles: Drug Dev. Ind. Pharm. 28: 265-274.
50. Zara GP, Bergoni A, Cavalli R, Fundaro A, Vighetto D, Gasco MR (2002) Pharmacokinetics and tissue distribution of Idarubicin - loaded solid lipid nanoparticles after duodenal administration to rats. J. Pharm. Sci. 91: 1324-1333.